Recombinant Human DEFB128 Protein ，His & Myc

Defensin Beta 128 (DEFB128) is a member of the beta defensin family, known for its role in the innate immune response. These small cationic peptides are primarily expressed in various epithelial tissues, including the skin, respiratory tract, and reproductive organs, where they function as antimicrobial agents against a broad spectrum of pathogens, including bacteria, viruses, and fungi. The interest in DEFB128 has surged due to its potential therapeutic applications, particularly in combating antibiotic-resistant infections and as a candidate for enhancing wound healing. Research has indicated that DEFB128 not only exhibits direct antimicrobial properties but also modulates inflammation and promotes the recruitment of immune cells to sites of infection. Furthermore, genetic variations in the DEFB128 gene have been associated with susceptibility to certain diseases, underlining its significance in human health. Recent advances in recombinant protein technology have enabled the production of DEFB128 in sufficient quantities for detailed study, facilitating investigations into its structure-function relationships and mechanisms of action. The exploration of DEFB128 as a therapeutic agent continues to be a promising area of research, with implications for developing new strategies to enhance innate immunity and address the growing challenge of infectious diseases. Overall, the multifaceted roles of DEFB128 in immune defense mechanisms and its potential for clinical application make it a compelling subject for ongoing scientific inquiry.